Custom Anti-idiotypic Antibodies
Antibody based drugs represent some of the most widely used therapies in medicine today.
Clinical studies into therapeutic chimeric, humanized or human antibodies require specialist detection tools, which have the ability to differentiate between the drug itself and naturally occurring immunoglobulin, which will always be present in human samples.
HuCAL® recombinant antibody production supports therapeutic drug development efficiently with highly specific, monoclonal, anti-idiotypic antibodies. HuCAL anti-idiotypic antibodies are ideal for preclinical research and generation of data to support the development of biosimilar antibody drugs. Their recombinant origin ensures:
Adalimumab (HUMIRA®) |
|
|
Alemtuzumab (LEMTRADATM) | ||
Bevacizumab (Avastin®) | ||
Cetuximab (ERBITUX®) | ||
Golimumab (Simponi®) | ||
Infliximab (REMICADE®) | ||
Natalizumab (Tysabri®) | ||
Omalizumab (Xolair®) | ||
Palivizumab (Synagis®) | ||
Panitumumab (Vectibix®) | ||
Rituximab (Rituxan®) | ||
Tocilizumab (Actemra®) | ||
Trastuzumab (Herceptin®) | ||
Ustekinumab (STELARA®) |
Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group. Avastin® is a registered trademark of Genentech, Inc. USA. ERBITUX® is a registered trademark of ImClone LLC. Herceptin® is a registered trademark of Genentech, Inc. USA. HuCAL® is a registered trademark of MorphoSys AG. HUMIRA® is a registered trademark of Abbott Laboratories. LEMTRADA® is a registered trademark of Genzyme Corporation. REMICADE® is a registered trademark of Janssen Biotech, Inc. USA. Rituxan® is a registered trademark of Biogen Idec, Inc. USA. Simponi® is a registered trademark of Centocor Ortho Biotech Inc. Stelara® is a registered trademark of Janssen Biotech, Inc. USA. Synagis® is a registered trademark of the AstraZeneca group of companies. Tysabri® is a registered trademark of Elan Pharmaceuticals, Inc. Vectibix® is a registered trademark of Amgen. Xolair® is a registered trademark of Genentech and Novartis.